Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments.

Yeoh HL, Cheng A, Palmer C, Crowe SM, Hoy JF.

Antivir Ther. 2017 Jul 21. doi: 10.3851/IMP3185. [Epub ahead of print]

PMID:
28731422
2.

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.

Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, Badal-Faesen S, de Wit S, Jacoby S, La Rosa A, Pujari S, Schechter M, White D, Engen NW, Ensrud K, Aagaard PD, Carr A; INSIGHT START Bone Mineral Density Substudy Group.

J Bone Miner Res. 2017 Jun 26. doi: 10.1002/jbmr.3183. [Epub ahead of print]

PMID:
28650589
3.

Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015.

Medland NA, Chow EPF, McMahon JH, Elliott JH, Hoy JF, Fairley CK.

PLoS One. 2017 May 16;12(5):e0177634. doi: 10.1371/journal.pone.0177634. eCollection 2017.

4.

Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.

Puhr R, Wright ST, Hoy JF, Templeton DJ, Durier N, Matthews GV, Russell D, Law MG.

Sex Health. 2017 May 9. doi: 10.1071/SH16151. [Epub ahead of print]

PMID:
28482168
5.

Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study.

Warren AM, Cheng AC, Watson K, Lewin SR, Hoy JF.

Sex Health. 2017 Apr 27. doi: 10.1071/SH16165. [Epub ahead of print]

PMID:
28445685
6.

Porphyromonas gingivalis antibody levels and diagnosis of coronary artery disease in HIV-positive individuals.

Berquist VL, Hearps AC, Ford P, Jaworowski A, Leishman SJ, Hoy JF, Trevillyan JM.

J Periodontal Res. 2017 Apr 10. doi: 10.1111/jre.12460. [Epub ahead of print]

PMID:
28397248
7.

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DFJ, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR.

AIDS. 2017 May 15;31(8):1137-1141. doi: 10.1097/QAD.0000000000001442.

PMID:
28301423
8.

Contribution of Common Infections to Cardiovascular risk in HIV Positive Individuals.

Berquist V, Hoy JF, Trevillyan JM.

AIDS Rev. 2017 Apr - Jun;19(2):72-80.

PMID:
28182619
9.

A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.

Callander D, Stoové M, Carr A, Hoy JF, Petoumenos K, Hellard M, Elliot J, Templeton DJ, Liaw S, Wilson DP, Grulich A, Cooper DA, Pedrana A, Donovan B, McMahon J, Prestage G, Holt M, Fairley CK, McKellar-Stewart N, Ruth S, Asselin J, Keen P, Cooper C, Allan B, Kaldor JM, Guy R.

BMC Infect Dis. 2016 Dec 12;16(1):752.

10.

Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system.

Pierce AB, El-Hayek C, McCarthy D, Armishaw J, Watson K, Wilkinson A, Price B, Wright EJ, Hoy JF, Stoové MA.

Sex Health. 2016 Dec 5. doi: 10.1071/SH16132. [Epub ahead of print]

PMID:
27914484
11.

Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals.

Trevillyan JM, Gardiner EE, Andrews RK, Maisa A, Hearps AC, Al-Tamimi M, Crowe SM, Hoy JF.

Platelets. 2017 May;28(3):301-304. doi: 10.1080/09537104.2016.1237627. Epub 2016 Nov 16.

PMID:
27848272
12.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA.

JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900.

13.

The HIV care cascade: a systematic review of data sources, methodology and comparability.

Medland NA, McMahon JH, Chow EP, Elliott JH, Hoy JF, Fairley CK.

J Int AIDS Soc. 2015 Nov 30;18:20634. doi: 10.7448/IAS.18.1.20634. eCollection 2015. Review.

14.

Effects of abacavir administration on structural and functional markers of platelet activation.

Trevillyan JM, Arthur JF, Jing J, Andrews RK, Gardiner EE, Hoy JF.

AIDS. 2015 Nov;29(17):2309-13. doi: 10.1097/QAD.0000000000000848.

PMID:
26544702
15.

Management guidelines for non-AIDS morbidity result in increased screening but no change in primary prevention implementation.

Trevillyan JM, Dart A, Topliss DJ, Walker RG, Whiting SE, Hoy JF.

AIDS. 2015 Mar 27;29(6):748-50. doi: 10.1097/QAD.0000000000000576. No abstract available.

PMID:
25849840
16.

Taming the great: enhanced syphilis screening in HIV-positive men who have sex with men in a hospital clinic setting.

Trubiano JA, Hoy JF.

Sex Health. 2015 Apr;12(2):176-8. doi: 10.1071/SH14164.

PMID:
25528423
17.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

18.

Hepatitis E in Australian HIV-infected patients: an under-recognised pathogen?

Yong MK, Paige EK, Anderson D, Hoy JF.

Sex Health. 2014 Sep;11(4):375-8. doi: 10.1071/SH13198.

PMID:
25162285
19.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):410-25. doi: 10.1001/jama.2014.8722.

PMID:
25038359
20.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

Supplemental Content

Loading ...
Support Center